Legal & General Group’s Eikon Therapeutics EIKN Stock Holding History

Legal & General Group’s Portfolio EIKN Stock Details EIKN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$27.6K	Buy	+2,118	New	+$21.6K	﹤0.01%	2984

Other funds holding EIKN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Legal & General Group's EIKN Position: Q2 2026 in Review

Legal & General Group opened a new position in Eikon Therapeutics (EIKN) in Q2 2026: 2,118 shares worth $27.6K. The stake represents ﹤0.01% of the portfolio and ranks #2984 among its holdings.

77 funds tracked by Wall St. Rank hold EIKN as of Q2 2026.

Legal & General Group held 2,118 shares of Eikon Therapeutics worth $27.6K as of Q2 2026.
Eikon Therapeutics was a new Legal & General Group position in Q2 2026.
Eikon Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2984 holding.
77 funds tracked by Wall St. Rank held Eikon Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.